Qiagen, Helix partner to advance CDx for hereditary diseases

Create PDF

February 2023—Qiagen announced an exclusive strategic partnership with Helix to advance companion diagnostics for hereditary diseases. Under the agreement, Qiagen will be the exclusive marketing and contracting partner in the United States for Helix’s companion diagnostic services.

“This partnership represents another step toward bringing the power of companion diagnostics to hereditary diseases by powering Helix’s leading products with Qiagen’s extensive pharma and biopharma relationships, NGS capabilities, and global regulatory expertise,” Thierry Bernard, chief executive officer of Qiagen, said in a joint press release. “Access to a genomic database can help researchers find patients with particular biomarker signatures almost instantaneously, making trial recruitment a matter of months instead of years.”

The partnership will leverage the Helix Laboratory platform, which was granted the first FDA de novo class II authorization for a whole exome sequencing platform. Qiagen’s companion diagnostic offerings encompass technologies from next-generation sequencing to polymerase chain reaction and digital PCR.

Qiagen, 240-686-7700
Helix, 844-211-2070